SCHEMBL7149958

SCHEMBL7149958

Cc1cc(CC(C)C)ccc1CCC=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.41
GABRB2 P47870 1/20 0.41
GPR84 Q9NQS5 1/20 0.35
PTGS1 P23219 3/20 0.33
PTGS2 P35354 3/20 0.33
LMNA P02545 2/20 0.33
CYP2C9 P11712 2/20 0.33
AKR1C3 P42330 2/20 0.33
CXCR1 P25024 2/20 0.33
CXCR2 P25025 2/20 0.33
ALB P02768 1/20 0.33
ESR1 P03372 1/20 0.33
ALOX5 P09917 1/20 0.33
RARB P10826 1/20 0.33
ADRB3 P13945 1/20 0.33
NFKB1 P19838 1/20 0.33
HTR2A P28223 1/20 0.33
NR1I3 Q14994 1/20 0.33
SLC22A6 Q4U2R8 1/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29362810 1.00 GABRA1 (0.41) GABRA1GABRB2GPR84PTGS1PTGS2
SCHEMBL17748405 0.91 GABRA1 (0.39) GABRA1GABRB2GPR84PTGS1PTGS2
SCHEMBL31680062 0.91 GABRA1 (0.39) GABRA1GABRB2GPR84PTGS1PTGS2
SCHEMBL16245734 0.87 GABRA1 (0.45) GABRA1GABRB2GPR84PTGS1PTGS2
SCHEMBL16245811 0.86
SCHEMBL16245756 0.86 GRIN2D (0.33)
SCHEMBL25317184 0.85 RXRA (0.32) MEN1KMT2A
SCHEMBL16245721 0.83 GRIN2D (0.43) LMNACYP2C9
SCHEMBL17748578 0.83 GABRA1 (0.40) GABRA1GABRB2GPR84PTGS1PTGS2
SCHEMBL16245763 0.81 TRPA1 (0.34) PTGS1PTGS2LMNAALOX5MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 681 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4214303-B1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2026-05-06 EP claimed
US-12589377-B2 Encapsulated composition comprising core-shell microcapsules and process for its preparation GIVAUDAN SA (CH) 2026-03-31 US claimed
EP-4711010-A2 PRO-PERFUME COMPOSITIONS Firmenich SA (CH) 2026-03-18 EP claimed
US-12559703-B2 Fragrance composition GIVAUDAN SA (CH) 2026-02-24 US claimed
US-12522786-B2 Organic compounds GIVAUDAN SA (CH) 2026-01-13 US claimed
EP-3218459-B1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2025-09-03 EP claimed
EP-3325588-B1 PERFUME COMPOSITIONS GIVAUDAN SA (CH) 2025-04-16 EP claimed
EP-3218341-B1 PHENYL BASED COMPOUNDS SUBSTITUTED WITH ALDEHYDE MOIETIES AND THEIR USE IN PERFUMERY GIVAUDAN SA (CH) 2024-05-01 EP claimed
EP-4356894-A1 SUSTAINABLE PRODUCT WITH MALODORS Beiersdorf AG (DE) 2024-04-24 EP claimed
EP-3800184-B1 ACETAL / KETAL-BASED FRAGRANCE AND INSECT REPELLENT PRECURSOR COMPOUNDS HENKEL AG & CO KGAA (DE) 2024-04-03 EP claimed
WO-2016074698-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2016-05-19 WO claimed
WO-2016074719-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2016-05-19 WO claimed
WO-2016074118-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2016-05-19 WO claimed
WO-2016074865-A1 PHENYL BASED COMPOUNDS SUBSTITUTED WITH ALDEHYDE MOIETIES AND THEIR USE IN PERFUMERY GIVAUDAN SA (CH) 2016-05-19 WO claimed
US-20160075627-A1 ORGANIC COMPOUNDS GIVAUDAN S.A. (CH) 2016-03-17 US claimed
EP-2994448-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS Givaudan SA (CH) 2016-03-16 EP claimed
WO-2015181257-A2 PERFUME COMPOSITIONS GIVAUDAN SA (CH) 2015-12-03 WO claimed
WO-2014180952-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2014-11-13 WO claimed
EP-0883675-B1 DETERGENT COMPOSITIONS CONTAINING ENDURING PERFUME PROCTER & GAMBLE (US) 2003-09-03 EP claimed
EP-0885279-B1 FABRIC SOFTENER COMPOSITION WITH IMPROVED ENVIRONMENTAL IMPACT PROCTER & GAMBLE (US) 2002-09-11 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12589377-B2 Encapsulated composition comprising core-shell microcapsules and process for its preparation CUTA, EXOC1, EXOSC10 GABRA1 3827/4885GABRB2 3959/4885GPR84 2087/4885
US-12559703-B2 Fragrance composition DHCR24, OPRD1, OR10J3 GABRA1 1256/4885GABRB2 1144/4885GPR84 766/4885
US-20160075627-A1 ORGANIC COMPOUNDS AOX1, TYR, ALK GABRA1 2048/4885GABRB2 2411/4885GPR84 101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.